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In-Utero Ex-Utero In+Ex Utero In-Utero vs.
Ex-Utero
In-Utero vs.
In+Ex Utero
Ex-Utero vs.
In+Ex Utero
P value P-value P-value
Volume (ml) N¼8,906 N¼6,305 N¼17,527 <0.0001 <0.0001 <0.0001
Median 64.0 54.0 77.1
(Range) (0.5-225.3) (0.2-289.0) (2.0-289.1)
Pre-Processing TNC (x107) N¼6,133 N¼3,514 N¼14,321 < 0.0001 < 0.0001 < 0.0001
Median 108.8 101.0 118.9
(Range) (15.3-1144.8) (13.7-829.5) (9-1359.1)
Post-Processing TNC (x107) N¼4,009 N¼2,124 N¼9,559 < 0.0001 < 0.0001 < 0.0001
Median 113.4 105.4 118.4
(Range) (13.4-602.0) (3.8-459.8) (28.9-679.7)
Post-processing CD34+ cells ( x106) N¼3,857 N¼2,009 N¼9,069 < 0.0001 0.7670 < 0.0001
Median 5.03 4.26 4.93
(Range) (0.36-57.64) (0-53.03) (0.03-63.36)
Microbial Contamination (%) N¼4,051
2.0
N¼2,107
0.5
N¼9,503
2.0
< 0.0001 0.8278 < 0.0001
Table
Correlation of MSKCC post-thaw results with NCBP pre-cryopreservation
CBU and segment evaluation
VCD34+ cells Specimen, Lab Specimen, Lab N R2 p
pre-cryo, NCBP segment, NCBP 68 0.85 <0.0001
segment, NCBP post-thaw, MSKCC 68 0.72 <0.0001
pre-cryo, NCBP post-thaw, MSKCC 68 0.70 <0.0001
CFU Specimen, Lab Specimen, Lab
pre-cryo, NCBP segment, NCBP 43 0.52 <0.001
segment, NCBP post-thaw, MSKCC 63 0.22 <0.001
pre-cryo, NCBP post-thaw, MSKCC 42 0.20 0.0017
v. viable CD34+ cells: N: number of CBU (not all CBU had pre-cryopreser-
vation CFU data).
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Chemo-Mobilization of Autologous Hematopoietic
Progenitor Cells (HPCs) with a Single Dose of
Pegﬁlgrastim and Supplemental Filgrastim in Patients
with Multiple Myeloma and Lymphoma: A Practical
Schema
Margaret R. McCallen, A. Sergio Torloni, Marin L. Jackson,
Matthew L. Ulrickson, Mary E. Peterson, Christine E. Adams,
Tracey D. Escalante, September Mitchell, Görgün Akpek.
Banner MD Anderson Cancer Center, Gilbert, AZ
Hematopoietic Progenitor Cell (HPC) mobilization should
take into consideration efﬁcacy, predictability, convenience
and cost. Despite many different schemas available, the
optimal growth factor regimen for chemo-mobilization is
still debatable. The standard growth factor used in HPC
mobilization is ﬁlgrastim (G-CSF) 10mcg/kg/day, adminis-
tered subcutaneously. Patients usually receive daily G-CSF
injections after chemotherapy in average of 10 days before
starting apheresis. Medicare patients have to go to hospital
or clinic every day to have their G-CSF injections given. We
retrospectively evaluated our experience with pegylated-
ﬁlgrastim given in conjunction with a subsequent short
course G-CSF in 15 patients (8F/7M) with multiple myeloma
(n¼6) and lymphoma (n¼9) who underwent chemo-growth
factor HPC mobilization for high-dose chemotherapy and
autologous stem cell transplantation. Median age was 68
(52-78). Chemotherapy regimen used for mobilizationwas at
the discretion of the transplant physician and included
cyclophosphamide (n¼2), DV-PACE (n¼5), DHAP (n¼2),
ESHAP (n¼2), EPOCH (n¼2), ICE (n¼1), mostly combined
with Rituximab. We planned ahead of time that chemo-
therapy is completed by the end of the week so that the
patient could spend the weekend at home and receive peg-
ﬁlgrastim at a single ﬁxed dose (6 mg) subcutaneously in the
following week with a median 3 (2-4) days after the last day
of chemotherapy. At the time of recovery when median WBC
was 0.6/mcL (0.1-3.8), daily G-CSF, at a median dose of 6mcg/
kg/day (5-12) was initiated in 5 (4-7) days after the dose of
pegﬁlgrastim. Five patients (33%) received additional Pler-
ixafor. HPC collection was started based on peripheral CD34
count in a median 3 days (1-6) after the initiation of G-CSF
and in 16 days (11-18) after the initial chemotherapy
administration. After 2 days (1-3) of apheresis, all patients
but one had adequate (>2 x 106) CD34+ cells/kg in HPC
product. Median CD34+ cell count on peripheral blood on
day+1 apheresis was 32 (4.6-407) x 106/kg. All patients had
full myeloid recovery and median time to ANC>500 x 3
consecutive days was 11 days (10-18) days. No graft failurewas observed. All patients tolerated the mobilization
regimen well with no serious side effects. Our preliminary
data suggest that single dose pegﬁlgrastim in conjunction
with low dose short course G-CSF can provide satisfactory
HPC mobilization and be considered an alternative conve-
nient growth factor regimen for select patients. A prospec-
tive study is currently underway in our institution.186
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Background: MSKCC analyses have shown that the infused
viable CD34+ cell dose is the critical determinant of neutro-
phil engraftment after CB transplantation (Purtill et al, Blood
2014). However, currently, CD34+ cell viability can only be
obtained on transplant day at unit thaw. Whether testing of
the segment attached to the freezing bag at the Bank prior to
unit release can predict the post-thaw CBU quality/potency
at the transplant center is not established.
Methods: We compared the post-thaw results of 68 NCBP
CBU, AXP-processed, stored in BioArchive freezers, shipped,
and thawed at MSKCC, with their respective segment and
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ogy to analyze cells from the thawed segment (w100 ul) for
CD34+ cell count and percent viability by ﬂow cytometry (7-
AAD exclusion using ISHAGE gating), and colony-forming
units (CFU) using high resolution digital imaging (Albano et
al, ASH 2008). At MSKCC, units were thawed using albumin-
dextran dilution, evaluated for CD34+ cell count & viability
(4-color ﬂow cytometry using modiﬁed ISHAGE gating
(Scaradavou et al, BBMT 2010), & CFU assays.
Results: At NCBP there was a high correlation between the
viable CD34+ cell counts and CFU in pre-cryopreservation
and segment data (Table). In the 68 CBU thawed at MSKCC,
the average decrease in CD34+ cell viability post-thaw
compared to that of the segment was 1.9% (SD:+/-3.9%;
p < 0.001) & ranged -11.0% to +12.0% with the lowest
post-thaw CD34+ cell viability being 82% (Figure 1).
Moreover, despite potential differences in laboratories
and ﬂow cytometric gating, the number of viable CD34+
cells in the unit post-thaw correlated with both the
pre-cryopreservation viable CD34+ counts and the results
of the segment (Table). The median viable CD34+ cell
recovery (ratio of post-thaw to segment viable CD34+
counts) was 128% (SD:+/-43.2). In contrast, however, post-
thaw CFU had weak correlation with pre-cryopreservation
and segment values (Table).
Conclusions: Testing of CBU segments can accurately
measure the potency of the frozen CB products, & segment
calculations may even underestimate the post-thaw CBU
CD34+ cell content. Although the decrease in post-thaw CBUFigure 1. Comparison of segment and post-thaw CBU CD34+ cell viability.CD34+ cell viability was statistically signiﬁcant, this
difference was too low to be clinically relevant. The poor
correlation between segment and post-thaw CFU likely
reﬂects signiﬁcant inter-laboratory assay variability.
These ﬁndings indicate that the processing procedures,
cryopreservation technology and thaw/dilution methodol-
ogy generate high quality units and that testing segment
CD34+ cell counts and the percentage of viable cells can
predict the post-thaw potency. Whether these ﬁndings can
be generalized to other CB banks and transplant centers
requires further investigation.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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MHC Class I Chain-Related Gene a (MICA) Donor-Recipient
Mismatches and MICA-129 Polymorphism in Unrelated
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Background: Previous reports from single centers suggested
that MICA polymorphism and donor/recipient MICA mis-
matches are associatedwith chronic graft versus host disease
(GVHD) and acute GVHD (respectively) after unrelated donor
HSCT. MICA is both a transplantation antigen and a ligand
recognized by the activating receptor NKG2D expressed by
NK, NKT, CD8+ and TCRgd+ Tcells. Allelic variants ofMICAdue
to a single amino acid substitution at position 129 result in
signiﬁcant differences in NKG2D binding. MICA alleles with a
methionine (M) or valine (V) have been classiﬁed as having
strong or weak binding afﬁnity for NKG2D, respectively.
Methods:We studied the association ofMICA polymorphism
(MICA-129) and MICA mismatches with unrelated donor
HSCT with 10/10 HLA match (n¼552 pairs) or 9/10 (HLA-B
mismatch only, n¼161 pairs), reported to the CIBMTR be-
tween 2000 and 2011. Included were adult patients who had
undergone a ﬁrst unrelated bonemarrow or peripheral blood
HSCT for ALL, AML, or MDS. Pre-transplant samples were
obtained from the NMDP Research Repository. MICA typing
was performed using rSSOP (One Lambda Thermo Fisher,
Canoga Park, CA). Study outcomes included overall survival,
disease-free survival, treatment-related mortality, relapse,
acute graft vs. host disease (GVHD), chronic GVHD, and
engraftment. Variables considered in multivariate analyses
included patient, disease and transplant characteristics. A p
value < 0.01 for the main effect was considered signiﬁcant.
Results: Of the recipients 101 wereMICA-129MM (14%), 363
MV (52%), and 239 VV (34%). Of the donors 106 were MICA-
129 MM (15%), 375 MV (53%), and 229 VV (32%). 27% of the
pairs were MICA mismatched, 9 pairs had double (one 10/10
and eight 9/10) and 182 had single mismatches (83 10/10 and
99 9/10). At 0.01 signiﬁcance level, there was no association
between any outcome and MICA mismatch or MICA-129
